Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production

Antiviral Research

Volumn 89, Issue 1, 2011, Pages 109-114

  Pan, Xiao Ben ^a   Wei, Lai ^a   Han, Jin Chao ^a   Ma, Hui ^a   Deng, Kai ^a   Cong, Xu ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Antivirus; Assembly; Cell penetrating peptide; Hepatitis B virus; Nucleocapsid

Indexed keywords

ARGININE DERIVATIVE; CELL PENETRATING PEPTIDE; VIRUS DNA;

ARTICLE; CELL MEMBRANE; CELL STRAIN HEPG2; CONTROLLED STUDY; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VIRUS ASSEMBLY; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS NUCLEOCAPSID; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; NUCLEOCAPSID; RECOMBINANT PROTEINS; VIRUS ASSEMBLY;

HEPATITIS B VIRUS;

EID: 78650895032     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.12.001     Document Type: Article

References (31)

1. Böttcher B., Tsuji N., Takahashi H., Dyson M.R., Zhao S., Crowther R.A., Murray K. Peptides that block hepatitis B virus assembly: analysis by cryomicroscopy, mutagenesis and transfection. EMBO J. 1998, 17:6839-6845.
2. Deres K., Schröder C.H., Paessens A., Goldmann S., Hacker H.J., Weber O., Krämer T., Niewöhner U., Pleiss U., Stoltefuss J., Graef E., Koletzki D., Masantschek R.N., Reimann A., Jaeger R., Gross R., Beckermann B., Schlemmer K.H., Haebich D., Rübsamen-Waigmann H. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003, 299:893-896.
3. Dyson M.R., Murray K. Selection of peptide inhibitors of interactions involved in complex protein assemblies: association of the core and surface antigens of hepatitis B virus. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:2194-2198.
4. Feld J.J., Colledge D., Sozzi V., Edwards R., Littlejohn M., Locarnini S.A. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res. 2007, 76:168-177.
5. Foged C., Nielsen H.M. Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin. Drug Deliv. 2008, 5:105-117.
6. Gerelsaikhan T., Tavis J.E., Bruss V. Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis. J. Virol. 1996, 70:4269-4274.
7. Hällbrink M., Florén A., Elmquist A., Pooga M., Bartfai T., Langel U. Cargo delivery kinetics of cell-penetrating peptides. Biochim. Biophys. Acta 2001, 1515:101-109.
8. Heermann K.H., Goldmann U., Schwartz W., Seyffarth T., Baumgarten H., Gerlich W.H. Large surface proteins of hepatitis B virus containing the pre-s sequence. J. Virol. 1984, 52:396-402.
9. Herce H.D., Garcia A.E., Litt J., Kane R.S., Martin P., Enrique N., Rebolledo A., Milesi V. Arginine-rich peptides destabilize the plasma membrane, consistent with a pore formation translocation mechanism of cell-penetrating peptides. Biophys. J. 2009, 97:1917-1925.
10. Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 1967, 26:365-369.
11. Kann M., Sodeik B., Vlachou A., Gerlich W.H., Helenius A. Phosphorylation-dependent binding of hepatitis B virus core particles to the nuclear pore complex. J. Cell. Biol. 1999, 145:45-55.
12. Karle I.L., Banerjee A., Balaram P. Design of two-helix motifs in peptides: crystal structure of a system of linked helices of opposite chirality and a model helix-linker peptide. Fold Des. 1997, 2:203-210.
13. King R.W., Ladner S.K., Miller T.J., Zaifert K., Perni R.B., Conway S.C., Otto M.J. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine. Antimicrob. Agents Chemother. 1998, 42:3179-3186.
14. Liaw Y.F., Chu C.M. Hepatitis B virus infection. Lancet 2009, 373:582-592.
15. Maiolo J.R., Ferrer M., Ottinger E.A. Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating peptides. Biochim. Biophys. Acta 2005, 1712:161-172.
16. Malik D.K., Baboota S., Ahuja A., Hasan S., Ali J. Recent advances in protein and peptide drug delivery systems. Curr. Drug Deliv. 2007, 4:141-151.
17. McLachlan A., Milich D.R., Raney A.K., Riggs M.G., Hughes J.L., Sorge J., Chisari F.V. Expression of hepatitis B virus surface and core antigens: influences of pre-S and precore sequences. J. Virol. 1987, 61:683-692.
18. Mohanty S.R., Kupfer S.S., Khiani V. Treatment of chronic hepatitis B. Natl. Clin. Pract. Gastroenterol. Hepatol. 2006, 3:446-458.
19. Ning B., Shih C. Nucleolar localization of human hepatitis B virus capsid protein. J. Virol. 2004, 78:13653-13668.
20. Pan X.B., Wei L., Han J.C., Gao Y. Cellular chromosome DNA interferes with fluorescence quantitative real-time PCR detection of HBV DNA in culture medium. J. Med. Virol. 2008, 80:47-52.
21. Poisson F., Severac A., Hourioux C., Goudeau A., Roingeard P. Both pre-S1 and S domains of hepatitis B virus envelope proteins interact with the core particle. Virology 1997, 228:115-120.
22. Ponsel D., Bruss V. Mapping of amino acid side chains on the surface of hepatitis B virus capsids required for envelopment and virion formation. J. Virol. 2003, 77:416-422.
23. Quan D.J., Peters M.G. Antiviral therapy, nucleotide and nucleoside analogs. Clin. Liver Dis. 2004, 8:371-385.
24. Reynaud L., Carleo M.A., Talamo M., Borgia G. Tenofovir and its potential in the treatment of hepatitis B virus. Ther. Clin. Risk Manag. 2009, 5:177-185.
25. Seeger C., Mason W.S. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 2000, 64:51-68.
26. Stray S.J., Zlotnick A. BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly. J. Mol. Recognit. 2006, 19:542-548.
27. Sung J.J., Wong M.L., Bowden S., Liew C.T., Hui A.Y., Wong V.W., Leung N.W., Locarnini S., Chan H.L. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005, 128:1890-1897.
28. Tan W.S. Inhibition of hepatitis B virus assembly with synthetic peptides derived from the viral surface and core antigens. J. Gen. Appl. Microbiol. 2002, 48:103-107.
29. Te H.S., Jensen D.M. Epidemiology of hepatitis B and C viruses, a global overview. Clin. Liver Dis. 2010, 14:1-21.
30. Yang H.I., Lu S.N., Liaw Y.F., You S.L., Sun C.A., Wang L.Y., Hsiao C.K., Chen P.J., Chen D.S., Chen C.J. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med. 2002, 347:168-174. Taiwan Community-Based Cancer Screening Project Group.
31. Zoulim F., Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009, 137:1593-1608.